Presentation platform
for clinical trials
On this page, current and planned clinical studies are presented by scientists of the Charité, who would like to present them on the Internet.
If you are interested in participating in one of the presented clinical studies, you can contact the corresponding clinic. The clinic will be displayed on the detail page after selecting the study.
You are here:
Filter results
NeuroMET2 - Metrologie und Innovation zur Früherkennung und genauen Stratifizierung von Patienten mit neurodegenerativen Erkrankungen
Short title: NeuroMET2
Investigated disease: AD
Principal Investigator: Laura Göschel
Patient (diseased)
Status: Participants wanted
Achtsamkeitsbasiertes Walki9ng bei Mama-Ca
Short title: Walkingstudie
Investigated disease: Fatigue bei Mammakarzinompatientinnen
Principal Investigator: Prof. Dr. Andreas Ströhle
Patient (diseased)
Age: 18 - 100
Gender: Female
Status: Participants wanted
PROSA
Short title: PROSA-Register
Investigated disease: acute symptomatic seizures
Principal Investigator: Prof. Dr. Martin Holtkamp
Patient (diseased)
Age: 18 - 199
Gender: All
Status: Participants wanted
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease
Short title: M16-006
Investigated disease: Morbus Crohn
Principal Investigator: Dr. med. Anja Schirbel
Patient (diseased)
Age: 18 - 80
Gender: All
Status: Participants wanted
Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).
Short title: Kura KO-TIP 007
Investigated disease: hnscc
Principal Investigator: PD Dr. med. Konrad Klinghammer
Patient (diseased)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Short title: M15-991
Investigated disease: M. Crohn
Principal Investigator: Dr. med. Anja Schirbel
Patient (diseased)
Age: 18 - 80
Gender: All
Status: Participants wanted
RIBANNA
Short title: RIBANNA
Investigated disease: Metastasiertes Hormonrezeptor positives Mammakarzinom
Principal Investigator: Verena Kiver
Patient (diseased)
Age: 18 - 99
Gender: Female
Status: Participants wanted
Macrogenics Solid
Short title: SOLID CPMGAO12-01
Investigated disease: Endometriumkarzinom
Principal Investigator: PD Dr. med. Sebastian Ochsenreither
Patient (diseased)
Status: Participants wanted
An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
Short title: Canfour CAN04
Principal Investigator: PD Dr. med. Sebastian Ochsenreither
Patient (diseased)
Age: 18 - 120
Gender: All
Status: Participants wanted
Collaborative Outcomes Study on Health and Functioning During Infection Times
Short title: COH-FIT
Investigated disease: General mental health
Principal Investigator: Prof. Dr. med. Christoph Correll
Proband (healthy)
Age: 6 - 99
Gender: All
Status: Participants wanted